Business Public Health Technology

Obesity Treatment Alternatives to Reshape Markets

Last updated: July 28, 2011 8:41 am

PatrickDriscoll

2 Min Read

Technologies to tackle the growing problem (and opportunity) of obesity globally have been undervalued as a result of adverse judgments by the FDA and the market against fledgling obesity drugs. It has been said that nature abhors a vacuum and, by analogy, the market for obesity treatment, driven by increasing prevalence, rapidly emerging data on the multiplying and costly effects of obesity’s complications, abhors a lack of new treatment options.

Technologies to tackle the growing problem (and opportunity) of obesity globally have been undervalued as a result of adverse judgments by the FDA and the market against fledgling obesity drugs. It has been said that nature abhors a vacuum and, by analogy, the market for obesity treatment, driven by increasing prevalence, rapidly emerging data on the multiplying and costly effects of obesity’s complications, abhors a lack of new treatment options. Manufacturers of device options and pharmaceuticals have generally not taken regulatory setbacks as a sign that the opportunity has diminished.

We forecast a robust market over the coming decade (with specific short-term milestone expected to buttress this) for both devices and drugs for the clinical management of obesity. See our forecast of the aggregate and composite obesity treatment market below:

Source: Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”

TAGGED:medical technology obesity public health

Share This Article

By PatrickDriscoll

Follow:

I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.